Plasma Aldosterone and Its Relationship with Left Ventricular Mass in Hypertensive Patients with Early-stage Chronic Kidney Disease

Overview

Journal Hypertens Res

Specialty Cardiology & Vascular Diseases

Date 2015 Jan 9

PMID 25567771

Citations 7

Authors

Giuseppe Mule

Emilio Nardi

Laura Guarino

Valentina Cacciatore

Giulio Geraci

Ilenia Calcaterra

Bruno Oddo

Francesco Vaccaro

Santina Cottone

Affiliations

Soon will be listed here.

Abstract

Plasma aldosterone concentrations (PACs) are often increased in the advanced stages of chronic kidney disease (CKD); however, PAC has not been fully investigated in early CKD. Moreover, little is known about the relationship between aldosteronemia and left ventricular (LV) mass in subjects with mild-to-moderate CKD. The study objectives were to analyze PAC, LV mass (LVM), LV geometry and their relationships, in a group of hypertensive patients with stage I-III CKD. One hundred ninety-five hypertensive patients with stage I-III CKD were enrolled and compared with a control group of 82 hypertensive patients without renal dysfunction. LVM was higher in subjects with CKD than in the control group and increased progressively with advancing stages of CKD (P=0.004). A similar trend was observed for PAC (P<0.0001), in which PAC was greater in CKD subjects with LV concentric geometry than in those with eccentric LV hypertrophy (P=0.01). Furthermore, in CKD patients, PAC was directly and significantly correlated with LVM (r=0.29; P<0.0001) and with relative wall thickness (RWT; r=0.36; P<0.0001). These associations remained significant even after adjustment for various confounding factors in multiple regression analyses (P<0.001). In summary, the results demonstrated that in CKD hypertensive patients, LVM, RWT and PAC are increased and related to each other from the earliest stages of renal dysfunction. Furthermore, it seems biologically plausible to speculate that aldosterone may promote a concentric geometry of the left ventricle and increase LVM in hypertensive patients with early CKD.

Citing Articles

Is echocardiography mandatory for patients with chronic kidney disease?.

Nardi E, Mule G, Nardi C, Geraci G, Giammanco A, Bentivegna R Intern Emerg Med. 2019; 14(6):923-929.

PMID: 30912000 DOI: 10.1007/s11739-019-02028-0.

The relationship between Aldosterone level and various LV conditions in patients with End-stage renal disease.

Nesarhosseini V, Mohsenipouya H, Makhlough A, Jalalian R Caspian J Intern Med. 2019; 10(1):36-41.

PMID: 30858939 PMC: 6386337. DOI: 10.22088/cjim.10.1.36.

Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?.

Nehme A, Zibara K Hypertens Res. 2017; 40(11):903-909.

PMID: 28680167 DOI: 10.1038/hr.2017.65.

Dual inhibitory action on aldosterone by combined angiotensin receptor antagonism and neprilysin inhibition.

Tamura K, Kobayashi R, Haku S, Azushima K, Wakui H Hypertens Res. 2016; 39(11):753-755.

PMID: 27334065 DOI: 10.1038/hr.2016.71.

The angiotensin II type 1 receptor-neprilysin inhibitor LCZ696 blocked aldosterone synthesis in a human adrenocortical cell line.

Miura S, Suematsu Y, Matsuo Y, Tomita S, Nakayama A, Goto M Hypertens Res. 2016; 39(11):758-763.

PMID: 27334058 DOI: 10.1038/hr.2016.72.

References

Cerasola G, Nardi E, Mule G, Palermo A, Cusimano P, Guarneri M . Left ventricular mass in hypertensive patients with mild-to-moderate reduction of renal function. Nephrology (Carlton). 2010; 15(2):203-10. DOI: 10.1111/j.1440-1797.2009.01178.x. View

Mule G, Nardi E, Cusimano P, Cottone S, Seddio G, Geraci C . Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome. Am J Hypertens. 2008; 21(9):1055-61. DOI: 10.1038/ajh.2008.225. View

Shigematsu Y, Hamada M, Mukai M, Matsuoka H, Sumimoto T, Hiwada K . Clinical evidence for an association between left ventricular geometric adaptation and extracardiac target organ damage in essential hypertension. J Hypertens. 1995; 13(1):155-60. View

Schambelan M, Sebastian A, Biglieri E . Prevalence, pathogenesis, and functional significance of aldosterone deficiency in hyperkalemic patients with chronic renal insufficiency. Kidney Int. 1980; 17(1):89-101. DOI: 10.1038/ki.1980.11. View

de Faria A, Demacq C, Figueiredo V, Moraes C, Santos R, Sabbatini A . Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension. Hypertens Res. 2013; 36(12):1067-72. DOI: 10.1038/hr.2013.92. View

Hostetter T, Ibrahim H . Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol. 2003; 14(9):2395-401. DOI: 10.1097/01.asn.0000086472.65806.73. View

De Simone G, Daniels S, Devereux R, Meyer R, Roman M, de Divitiis O . Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol. 1992; 20(5):1251-60. DOI: 10.1016/0735-1097(92)90385-z. View

DeFronzo R . Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int. 1980; 17(1):118-34. DOI: 10.1038/ki.1980.14. View

Cottone S, Mule G, Guarneri M, Palermo A, Lorito M, Riccobene R . Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant. 2008; 24(2):497-503. DOI: 10.1093/ndt/gfn489. View

10.

Schunkert H, Hense H, Muscholl M, Luchner A, Kurzinger S, Danser A . Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart. 1997; 77(1):24-31. PMC: 484630. DOI: 10.1136/hrt.77.1.24. View

11.

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

12.

Hene R, Boer P, Koomans H, Mees E . Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 1982; 21(1):98-101. DOI: 10.1038/ki.1982.14. View

13.

Nardi E, Palermo A, Mule G, Cusimano P, Cottone S, Cerasola G . Left ventricular hypertrophy and geometry in hypertensive patients with chronic kidney disease. J Hypertens. 2009; 27(3):633-41. DOI: 10.1097/HJH.0b013e3283220ecd. View

14.

Malmqvist K, Ohman K, Lind L, Nystrom F, Kahan T . Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin. J Intern Med. 2003; 252(5):430-9. DOI: 10.1046/j.1365-2796.2002.01053.x. View

15.

Iwashima Y, Horio T, Kuroda S, Takishita S, Kawano Y . Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. Hypertens Res. 2002; 25(1):49-56. DOI: 10.1291/hypres.25.49. View

16.

Rossi G, Albertin G, Neri G, Andreis P, Hofmann S, Pessina A . Endothelin-1 stimulates steroid secretion of human adrenocortical cells ex vivo via both ETA and ETB receptor subtypes. J Clin Endocrinol Metab. 1997; 82(10):3445-9. DOI: 10.1210/jcem.82.10.4279. View

17.

Weidmann P, Maxwell M, Rowe P, Winer R, Massry S . Role of the renin-angiotensin-aldosterone system in the regulation of plasma potassium in chronic renal disease. Nephron. 1975; 15(1):35-49. DOI: 10.1159/000180491. View

18.

Lang R, Bierig M, Devereux R, Flachskampf F, Foster E, Pellikka P . Recommendations for chamber quantification. Eur J Echocardiogr. 2006; 7(2):79-108. DOI: 10.1016/j.euje.2005.12.014. View

19.

Sato A, Funder J, Saruta T . Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens. 1999; 12(9 Pt 1):867-73. DOI: 10.1016/s0895-7061(99)00066-7. View

20.

Edwards N, Steeds R, Stewart P, Ferro C, Townend J . Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009; 54(6):505-12. DOI: 10.1016/j.jacc.2009.03.066. View